| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5217 | Trans-cbtbp | Novel KGA allosteric inhibitor |
|
| DCC5218 | Trans-miyabenol C | Natural resveratrol trimer, acting as a protein kinase C inhibitor |
|
| DCC5219 | Trans-ocma | Natural specific inhibitor of γ-secretase, decreasing amyloid-beta levels without influencing cleavage of Notch, showing strong growth inhibitory effects on cancer cell lines and significant anti-complement activity, also acting as a PTP1B inhibitor |
|
| DCC5220 | trans-resveratrol-3-o-glucuronide | Metabolite of Resveratrol |
|
| DCC5221 | trans-resveratrol-4'-o-glucuronide | Metabolite of Resveratrol |
|
| DCC5222 | Trantinterol | Novel Highly Selective β2-Adrenoceptor Agonist as an Oral Antiasthmatic Agent |
|
| DCC5223 | trapoxin B | Inhibitor of histone deacetylases |
|
| DCC5224 | Trc210258 | Novel TGR5 agonist, reducing glycemic and dyslipidemic cardiovascular risk in animal models of diabesity |
|
| DCC5225 | Trehalose-6-phosphate | Central sugar signal in plants, regulating sucrose use and allocation, underpinning crop growth and development |
|
| DCC5226 | Trenbolone Enanthate | Potent and long-acting derivative of the hormone Trenbolone |
|
| DCC5227 | Triazophos | EC 3.1.1.7 (Acetylcholinesterase) inhibitor, acting as an insecticide, an acaricide, an agrochemical, and a nematicide |
|
| DCC5228 | Triciribine Phosphate | AKT Inhibitor, Enhancing Gemcitabine Activity in Pancreatic Cancer Cells |
|
| DCC5229 | Tridecyl 2-aminoacetate Hydrochloride | Potent NAE-hydrolyzing acid amidase (NAAA) inhibitor |
|
| DCC5230 | Trifluoperazine N-glucuronide | Metabolite of Trifluoperazine; Antidepressant and antipsychotic |
|
| DCC5231 | Trifluoroacetyl Lysine | Novel Bromodomain Binding Mimic of Lysine Acetylation |
|
| DCC5232 | Trigonellinamide | Metabolite of nicotinamide; Specific and potent inhibitor of NNMT, increasing histone methylation at H3K4 and methylated H3K4 occupancy at gene promoters |
|
| DCC5233 | Trimipramine | Antipsychotic and sedative agent as a potent antagonist of H1, 5-HT2A, and alpha1-adrenergic receptors |
|
| DCC5234 | Tripartin | Specific inhibitor of the histone H3 lysine 9 demethylase KDM4 in HeLa cells. |
|
| DCC5235 | Triplin | Copper ion chelator, causing the triple response phenotype by affecting copper ion transport in ethylene signaling from ATX1 to RAN1 |
|
| DCC5236 | Tritiozine | Novel anti-secretory and antiulcer agent for treatment of peptic ulcer disease and hypersecretory disorders |
|
| DCC5237 | Trk Inhibitor 7d | First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitor that Overcome Clinically Acquired Resistance |
|
| DCC5238 | Trk-130 | Novel opioid ligand for treatment of overactive bladder, acting as a μ-opioid receptor partial agonist |
|
| DCC5239 | Trka-in-1 | Novel potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) |
|
| DCC5240 | trmd-in-51 | First-in-class highly potent and selective inhibitor of TrmD (bacterial t-RNA-(N1G37) methyltransferase) |
|
| DCC5241 | Tropanserin | Potent and selective 5-HT3 receptor antagonist |
|
| DCC5242 | Tropisetron | Serotonin 5-HT3 receptor antagonist |
|
| DCC5243 | Trovafloxacin | Fluroquinolone antibiotic, suppressing c-Myc transcription and myeloma growth, inhibiting pannexin-1 channels through which ATP is released as find-me signals in apoptotic Jurkat cells |
|
| DCC5244 | Trpa1 Agonist 2c | Novel Photosensitive and Photoswitchable TRPA1 Agonist, Optically Control Pain through Channel Desensitization |
|
| DCC5245 | Trpa1-in-2 | Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain |
|
| DCC5246 | Trpa1-in-3 | Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain |
|
